These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 29579828)

  • 21. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation.
    Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus.
    Leino AD; Emoto C; Fukuda T; Privitera M; Vinks AA; Alloway RR
    Am J Transplant; 2019 Oct; 19(10):2944-2948. PubMed ID: 31012522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.
    Valvassori SS; Elias G; de Souza B; Petronilho F; Dal-Pizzol F; Kapczinski F; Trzesniak C; Tumas V; Dursun S; Chagas MH; Hallak JE; Zuardi AW; Quevedo J; Crippa JA
    J Psychopharmacol; 2011 Feb; 25(2):274-80. PubMed ID: 19939866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
    Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
    Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabidiol monotherapy for treatment-resistant schizophrenia.
    Zuardi AW; Hallak JE; Dursun SM; Morais SL; Sanches RF; Musty RE; Crippa JA
    J Psychopharmacol; 2006 Sep; 20(5):683-6. PubMed ID: 16401651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
    Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of calcineurin inhibitors on paraoxonase and arylesterase activity after a kidney transplant.
    Kahvecioglu S; Ersoy A; Gullulu M; Dirican M
    Exp Clin Transplant; 2014 Aug; 12(4):334-42. PubMed ID: 24447269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients.
    Krejci K; Zadrazil J; Lackova E; Zilinska Z; Roland R; Dedinska I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Sep; 160(3):407-11. PubMed ID: 27174195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation.
    Barone GW; Ketel BL; Abul-Ezz SR; Lightfoot ML
    JOP; 2002 Mar; 3(2):49-53. PubMed ID: 11884766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.
    Katari SR; Magnone M; Shapiro R; Jordan M; Scantlebury V; Vivas C; Gritsch A; McCauley J; Starzl T; Demetris AJ; Randhawa PS
    Clin Transplant; 1997 Jun; 11(3):237-42. PubMed ID: 9193849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus.
    Lauzurica R; Morales JM; van Hooff J;
    Transpl Int; 2012 Jan; 25(1):48-55. PubMed ID: 21992068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cannabidiol for the treatment of psychosis in Parkinson's disease.
    Zuardi AW; Crippa JA; Hallak JE; Pinto JP; Chagas MH; Rodrigues GG; Dursun SM; Tumas V
    J Psychopharmacol; 2009 Nov; 23(8):979-83. PubMed ID: 18801821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insulin requirement after a renal transplant in patients with type 2 diabetes: the choice of calcineurin inhibitors.
    van den Hoogen MW; van der Hoeven AM; Hilbrands LB
    Exp Clin Transplant; 2013 Jun; 11(3):234-8. PubMed ID: 23432070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion from cyclosporine to tacrolimus in pediatric kidney transplant recipients.
    Ferraresso M; Ghio L; Edefonti A; Garavaglia R; Berardinelli L
    Pediatr Nephrol; 2002 Aug; 17(8):664-7. PubMed ID: 12185478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial.
    Naftali T; Mechulam R; Marii A; Gabay G; Stein A; Bronshtain M; Laish I; Benjaminov F; Konikoff FM
    Dig Dis Sci; 2017 Jun; 62(6):1615-1620. PubMed ID: 28349233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-month experience with tacrolimus once-daily regimen in stable renal allografts.
    Diez Ojea B; Alonso Alvarez M; Aguado Fernández S; Baños Gallardo M; García Melendreras S; Gómez Huertas E
    Transplant Proc; 2009; 41(6):2323-5. PubMed ID: 19715908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.